Estimation of the Prevalence of Microcirculatory Dysfunction in Uremic Cardiopathy Among Dialysis Patients

ConditionHemodyalysis
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-90
SponsorCentre Hospitalier Departemental Vendee

About this trial

Patients with end-stage renal disease have a high burden of cardiovascular mortality, yet ischemic heart disease is often asymptomatic and difficult to diagnose in this population. Recent data suggest that microvascular coronary dysfunction may contribute significantly to myocardial ischemia in dialysis patients, but its true prevalence remains unknown. This study aims to evaluate microcirculatory coronary impairment in hemodialysis patients using invasive coronary angiography with measurement of coronary flow reserve (CFR), index of microcirculatory resistance (IMR). The study will also describe the clinical and biological characteristics associated with microvascular dysfunction in this population, in order to better understand the mechanisms of uremic cardiomyopathy and improve cardiovascular risk stratification.

Eligibility criteria

Qualifiers

Age ≥ 18 years

Patients who have been on haemodialysis for at least 6 months

Elevated troponin levels > 40 ng/L in a sample taken whilst the patient was in a stable condition, dated within the last 3 months

Patients capable of understanding the protocol and who have given their written informed consent to participate in the research

Disqualifiers

Age > 90 years

Patient undergoing daily home haemodialysis

Symptomatic stage 3 or 4 peripheral arterial disease

Severe hypertrophic cardiomyopathy (genetic or amyloid)

Trial design

Treatments tested in this trial

  • Transthoracic ultrasound at rest
  • Cardiological stress test
  • Coronary angiography

Treatment groups

No treatment groups listed